Evidence Table 133. KQ3—Dichotomous—Gastrointestinal adverse events

| **Author Year****Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug****(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Davidson200714Parallel | NR | Unclear | Simvastatin (40) | Omega-3 | 122 | 5 | Placebo | 132 | 3 |  |  | Medium |
| D’Arcangues200413Parallel | NR | Mixed: Low and/or Moderate | ASA (80) | Vitamin E | 121 |  | No Treatment | 122 |  |  | Treatment course was for 10 days. But followup went on for up to 1 year. | Medium |
| Garg199524Parallel | NR | At high risk for CHD | ASA and/or pentoxiphylline (NR) | Ginkgo biloba | 29 | 4 | Placebo | 26 | 3 |  |  | Medium-high |
| Roth200960Parallel | NR | Unclear | Fenofibrate (130) | Omega-3 | 84 | 7 | Placebo | 83 | 5 |  |  | Medium |
| Dehmer198817Parallel | belching, dyspepsia flatulence in tx group vs. Dyspepsia in control group | At high risk for CHD | Aspirin (325)+ Dipyridamole (225) + Calcium channel blockers (NR) | Omega-3 | 43 | 7 | No Treatment | 39 | 3 |  |  | Medium |
| Eritsland199621Parallel | NR | At high risk for CHD | Warfarin (NR) | Omega-3 | 174 | 9 | No Treatment | 145 | 0 |  |  | Medium  |
| Eritsland199621Parallel | NR | At high risk for CHD | Aspirin (300) | Omega-3 | 143 | 7 | No Treatment | 148 | 12 |  |  | Medium  |
| Maki200841Crossover | N/A | Mixed:Low, Moderate and high risk | Simvastatin (20) | Omega-3 | 40 | 1 | Placebo | 40 | 1 |  |  | Medium |

Evidence Table 133. KQ3—Dichotomous—Gastrointestinal adverse events (continued)

| **Author Year****Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug****(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Wolf200668Crossover | N/A | Mixed:Low and/or Moderate | ASA (500) | Ginkgo biloba | 50 | 6 | Placebo | 50 | 9 |  |  | Low-medium |
| Mauro200343Crossover | N/A | At low risk for CHD (0-1 risk factors) | Digoxin (0.5 single dose) | Ginkgo biloba |  | 1 | No Treatment |  |  |  |  | Medium |